All news from Anaesthesiology

Severe Chronic Plaque Psoriasis Treated With Tildrakizumab

A study recommends in favor of the interleukin (IL)-23 inhibitor tildrakizumab (Ilumetri, Almirall SA) for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.

Tildrakizumab reduces the immune response and inflammatory process, leading to improvement in the signs and symptoms of plaque psoriasis, the EMA says in a press statement. The most common side effects are upper respiratory tract infections, gastroenteritis, nausea, diarrhea, headache, injection site pain, and back pain.